Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
By D. Cunningham, W. Allum, S. Stenning, Jeremy N. Thompson, C. J. van de Velde, M. Nicolson, J. Howard Scarffe, F. Lofts, S. Falk, T. Iveson and 6 more. New England Journal of Medicine, 2006
6,007 citations recorded by the source corpus.
Subfields: Gastroenterology, Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/92433865fee3849a211dc625f63b13b0e4a662bc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Gastroenterology
In Pulmonary and Respiratory Medicine
In Surgery
Citations in the corpus
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010, neutral): “The UK MRC MAGIC trial demonstrated an improvement in 5-year survival from 23% to 36% for patients with resectable stage II and III gastric cancers treated with six cycles (three preand three postoperative) of perioperative ECF chemotherapy [epirubicin, cisplatin and 5-fluorouracil (5-FU)] compared ”
- miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells (2008, background): “Chemotherapy remains the primary treatment for both resectable and advanced gastric cancer as to improving overall survival and quality of life for patients.(2,3) In many cases, however, therapies fail because of multidrug resistance (MDR) of cancer cells either intrinsic or acquired after an initia”
- Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. (2008, background): “shown benefit in selected individual trials in patients with gastric and gastroesophageal junction cancers.(1,2)”